Effects of IL-10 haplotype and atomic bomb radiation exposure on gastric cancer risk

Radiation Research

Volumn 180, Issue 1, 2013, Pages 60-69

  Hayashi, Tomonori ^a   Ito, Reiko ^a   Cologne, John ^a   Maki, Mayumi ^a   Morishita, Yukari ^a   Nagamura, Hiroko ^a   Sasaki, Keiko ^a   Hayashi, Ikue ^b   Imai, Kazue ^a   Yoshida, Kengo ^a   Kajimura, Junko ^a   Kyoizumi, Seishi ^a   Kusunoki, Yoichiro ^a   Ohishi, Waka ^a   Fujiwara, Saeko ^a   Akahoshi, Masazumi ^a   Nakachi, Kei ^a  

^a RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ADULT; AGED; ALLELE; ARTICLE; ATOMIC BOMB; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; DOSE RESPONSE; EXPOSURE; FEMALE; GENDER; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SURVIVOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE-ENVIRONMENT INTERACTION; HAPLOTYPES; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NUCLEAR WEAPONS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIATION DOSAGE; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84880567567     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR3183.1     Document Type: Article

References (43)

1. Pierce DA, Preston DL. Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat Res 2000; 154:178-86. (Pubitemid 30612918)
2. Pierce DA, Shimizu Y, Preston DL, Vaeth M, Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990. Radiat Res 1996; 146:1-27. (Pubitemid 26230829)
3. Shimizu Y, Kato H, Schull WJ. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). Radiation research 1990; 121:120-41. (Pubitemid 20091317)
4. Shimizu Y, Kato H, Schull WJ. Risk of cancer among atomic bomb survivors. J Radiat Res (Tokyo) 1991; 32 Suppl 2:54-63.
5. Peek RM, Jr. Pathogenesis of Helicobacter pylori infection. Springer Semin Immunopathol 2005; 27:197-215. (Pubitemid 41291625)
6. Rosenstiel P, Hellmig S, Hampe J, Ott S, Till A, Fischbach W, et al. Influence of polymorphisms in the NOD1/CARD4 and NOD2/ CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell Microbiol 2006; 8:1188-98. (Pubitemid 43871652)
7. Seno H, Satoh K, Tsuji S, Shiratsuchi T, Harada Y, Hamajima N, et al. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: comprehensive analysis of 207 polymorphisms of 11 cytokine genes. J Gastroenterol Hepatol 2007; 22:729-37. (Pubitemid 46608392)
8. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005; 78:1043-51. (Pubitemid 41572467)
9. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81:2964-71. (Pubitemid 23162114)
10. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24.
11. Wojciechowska-Lacka A, Matecka-Nowak M, Adamiak E, Lacki JK, Cerkaska-Gluszak B. Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma 1996; 43:155-8. (Pubitemid 26229349)
12. Avradopoulos K, Mehta S, Blackinton D, Wanebo HJ. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol 1997; 4:184-90. (Pubitemid 127729063)
13. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996; 88:536-41. (Pubitemid 26118724)
14. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 1999; 19:697-703. (Pubitemid 29379811)
15. Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, et al. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene therapy 1999; 6:1705-12. (Pubitemid 29485945)
16. Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg JS. A single amino acid determines the immunostimulatory activity of inter-leukin 10. J Exp Med 2000; 191:213-24.
17. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunologic Res 2011; 51:170-82.
18. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics 1997; 46:120-8. (Pubitemid 27234709)
19. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. Interindi-vidual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003; 75:711-7. (Pubitemid 36337373)
20. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet 1997; 24:1-8. (Pubitemid 27050850)
21. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124:1193-201. (Pubitemid 36531795)
22. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, et al. Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. J Gastroenterol Hepatol 2007; 22:1443-9. (Pubitemid 47274569)
23. Xue H, Lin B, An J, Zhu Y, Huang G. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer 2012;12: 102.
24. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. Interleukin-10 - 1082 promoter polymorphism associated with gastric cancer among Asians. Eur J Cancer 2008; 44:2648-54.
25. Lee JY, Kim HY, Kim KH, Kim SM, Jang MK, Park JY, et al. Association of polymorphism of IL-10 and TNF - A genes with gastric cancer in Korea. Cancer Lett 2005; 225:207-14.
26. Bai XL, Sun LP, Liu J, Chen W, Zhang Y, Yuan Y. [Correlation of interleukin-10-1082G/a single nucleotide polymorphism to the risk of gastric cancer in north China: a case-control study]. Ai Zheng 2008; 27:35-40.
27. Xiao H, Jiang Y, Li R, Xia B. [Association of IL-10 gene polymorphisms with gastroduodenal diseases in Hubei Han population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2009; 26:423-6.
28. Chen KF, Li B, Wei YG, Peng CJ. Interleukin-10 - 819 promoter polymorphism associated with gastric cancer among Asians. J Int Med Res 2010; 38:1-8.
29. Yamada M, Wong FL, Fujiwara S, Akahoshi M, Suzuki G Noncancer disease incidence in atomic bomb survivors, 1958-1998. Radiat research 2004; 161:622-32. (Pubitemid 39149570)
30. Wong FL, Yamada M, Sasaki H, Kodama K, Akiba S, Shimaoka K, et al. Noncancer disease incidence in the atomic bomb survivors: 1958-1986. Radiat Res 1993; 135:418-30. (Pubitemid 23306530)
31. Suzuki G, Cullings H, Fujiwara S, Hattori N, Matsuura S, Hakoda M, et al. Low-positive antibody titer against Helicobacter pylori cytotoxin-associated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori. Cancer Epidemiol Biomarkers Prev 2007; 16:1224-8. (Pubitemid 46984963)
32. Hanai A, Fujimoto I. Cancer incidence in Japan in 1975 and changes of epidemiological features for cancer in Osaka. Natl Cancer Inst Monograph 1982; 62:3-7. (Pubitemid 13102212)
33. Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 2001; 84:400-5. (Pubitemid 32154436)
34. De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA. New generation pharmacogenomic tools: a SNP linkage disequilibrium Map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques 2002; Suppl: 48-50, 2,4.
35. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291:1304-51. (Pubitemid 32173090)
36. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Biomol Eng 1999; 14:143-9. (Pubitemid 29095371)
37. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies on mortality of atomic bomb survivors: Solid cancer and noncancer disease mortality: 1950-1997. RERF Report No 24-02, Radiation Effects Research Foundation, Hiroshima, Japan.
38. Cologne J, Hsu WL, Abbott RD, Ohishi W, Grant EJ, Fujiwara S, et al. Proportional hazards regression in epidemiologic follow-up studies: an intuitive consideration of primary time scale. Epidemiology 2012; 23:565-73.
39. Cullings HM, Fujita S, Funamoto S, Grant EJ, Kerr GD, Preston DL. Dose estimation for atomic bomb survivor studies: its evolution and present status. Radiat Res 2006; 166:219-54. (Pubitemid 44051213)
40. Greenland S. Tests for interaction in epidemiologic studies: a review and a study of power. Stat Med 1983; 2:243-51. (Pubitemid 13020136)
41. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980; 112:467-70. (Pubitemid 10029548)
42. Cologne JB, Pawel DJ, Sharp GB, Fujiwara S. Uncertainty in estimating probability of causation in a cross-sectional study: joint effects of radiation and hepatitis-C virus on chronic liver disease. J Radiol Protect 2004; 24:131-45. (Pubitemid 38967964)
43. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter 2007; 12:1-15. (Pubitemid 46105914)